Results 171 to 180 of about 51,825 (261)

The Baraitser–Winter Cerebrofrontofacial Syndrome Recurrent R196H Variant in Cytoplasmic β‐Actin Impairs Its Cellular Polymerization and Stability

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
BWCFF, a severe disease with neurological symptoms, is caused by mutations in the cytoskeletal actin genes. Patient‐derived fibroblasts carrying the R196H β‐actin mutation were compared to wild type cells. The mutant cells displayed slower proliferation and migration and a lower F‐actin content, which correlated with reduced cell stiffness ...
Éva Gráczer, Elena Battirossi, Tamás Bozó, Áron Gellért Altorjay, Katalin Pászty, Laura Harsányi, Johannes N. Greve, Irene Pertici, Massimo Reconditi, Nataliya Di Donato, Miklós Kellermayer, Pasquale Bianco, Andrea Varga   +12 more
wiley   +1 more source

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis. [PDF]

Arch Med Sci Atheroscler Dis
Hazique M, Lohana S, Kafle S, Bhinder J, Patel KN, Basit J, Bahar AR, Kvapil J, Alraies MC.   +8 more
europepmc   +1 more source

Non-muscle myosin II is a promising therapeutic target. [PDF]

Trends Pharmacol Sci
Miller CA, Quinones-Hinojosa A, Rosenfeld SS.   +2 more
europepmc   +1 more source

Biogenesis of Organelles and Membrane Proteins. [PDF]

, 1988
Harmey, Matthew A., Neupert, Walter, Nicholson, Donald W., Stuart, Rosemary A.   +3 more
core   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. [PDF]

J Clin Med
Mansour GK, Altebainawi AF, Hajjar AW, Sayed SBH, Alazem FA, Sajid MR.   +5 more
europepmc   +1 more source

Cardiac myosin inhibitors: a silver lining for an old disease

Open Heart
Satyavir Yadav, Sourabh Agstam, Sandeep Singh   +2 more
openaire   +2 more sources

PTUPB, a soluble epoxide hydrolase/cyclooxygenase‑2 dual inhibitor, reduces endothelial‑to‑mesenchymal transition and improves doxorubicin‑induced vascular and cardiac toxicity. [PDF]

Mol Med Rep
Dhulkifle H, Therachiyil L, Hasan MH, Younis SM, Al-Shar'i NA, Yalcin HC, Maayah ZH.   +6 more
europepmc   +1 more source

Cellular and Molecular Mechanisms of Heart Failure and Sudden Cardiac Death in Hypertrophic Cardiomyopathy and Methods Used for Their Pathogenetic Correction. [PDF]

Biomedicines
Kakturskiy L, Belov Y, Mikhaleva L, Lysenko A, Gioeva Z, Tikhonova N, Gutyrchik N.   +6 more
europepmc   +1 more source

Myosin Mayhem: Losing (or Gaining) Its Chill in Hypertrophic Cardiomyopathy. [PDF]

Circ Heart Fail
Colson BA.
europepmc   +1 more source

Long-Term Real-World Outcomes of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy up to 108 Weeks. [PDF]

J Clin Med
Reza N, Dubey A, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Marzolf A, Hornsby N, de Feria A, Carattini T, Schuler P, Owens AT.   +12 more
europepmc   +1 more source